C3N-03486
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 65.29500342
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.450
- OXIDATIVE_PHOSPHORYLATION+0.370
- E2F_TARGETS+0.350
- KRAS_SIGNALING_DN+0.350
- INTERFERON_ALPHA_RESPONSE+0.330
- INTERFERON_GAMMA_RESPONSE+0.320
- UV_RESPONSE_UP+0.260
- ESTROGEN_RESPONSE_LATE+0.230
- G2M_CHECKPOINT+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
Top 10 suppressed
- TGF_BETA_SIGNALING-0.530
- PROTEIN_SECRETION-0.470
- ANGIOGENESIS-0.440
- UV_RESPONSE_DN-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- ANDROGEN_RESPONSE-0.320
- HEDGEHOG_SIGNALING-0.260
- COAGULATION-0.240
- KRAS_SIGNALING_UP-0.240
- APICAL_JUNCTION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AO-A1KQ-01A-11R-A13Q-07 | — | B | 0.821 |
| 2 | TCGA-A2-A3Y0-01A-11R-A239-07 | — | E | 0.818 |
| 3 | TCGA-D8-A1XL-01A-11R-A14M-07 | — | B | 0.815 |
| 4 | TCGA-KU-A6H7-01A-11R-A31N-07 | — | — | 0.813 |
| 5 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.809 |
| 6 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.795 |
| 7 | TCGA-A2-A4S3-01A-21R-A266-07 | — | B | 0.784 |
| 8 | SRR8518141 | — | E | 0.779 |
| 9 | TCGA-A7-A6VW-01A-21R-A33J-07 | — | E | 0.774 |
| 10 | c4779698-5c81-4eed-80ac-80fdd47f658b | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |